About
About Sermorelin Prescribed
A safety-and-tolerability reading of the GHRH(1-29) record — what the studies measured, and what this desk is not.
What this site is
Sermorelin Prescribed keeps a case file on the peer-reviewed research into sermorelin (GHRH(1-29)), opened around a single question: what the published record actually establishes about safety and tolerability. It is a reading of that literature, not a service attached to it. Nobody here diagnoses, treats, or prescribes, and nobody hands out medical advice — there is no clinic, no pharmacy counter, no clinician on call. Nothing is manufactured, stocked, priced, or sold; the file holds citations, not products.
The site reads the literature through a single deliberate lens — safety and tolerability — because that is where the gap between public perception and published evidence is widest. We summarize what the studies measured, attribute every quantitative claim to its source, and mark plainly where the data are thin.
What "prescribed" means here
The word "prescribed" in this site's name is editorial framing — a position this publisher occupies relative to the literature, not a claim about services we offer. We do not write prescriptions, take patients, or operate a pharmacy. We do not employ doctors, pharmacists, or any clinical team, and we do not offer treatment, consultation, or prescription services of any kind.
The distinction matters for sermorelin specifically, because its real history is easy to misstate. Sermorelin was a genuinely FDA-approved drug for pediatric growth-hormone deficiency, withdrawn from the US market in 2008 for commercial — not safety or efficacy — reasons, and is now prepared by compounding pharmacies. "Prescribed" here points at that documented regulatory story, read as editorial commentary, never at any service this site provides.
How we handle the evidence
Every figure on this site is carried back to a named study, listed in full on the references page. Where a finding comes from a related GHRH analogue rather than from sermorelin itself — the body-composition and cognition numbers, for instance, which come from tesamorelin trials — we say so, rather than letting drug-class results stand in for sermorelin results.
We describe research findings only. We do not recommend doses for any person, we use studied-at-X framing for every figure, and we treat the limits of the literature as part of the record worth reporting. When authorities have judged a use unproven, we cite that judgment alongside the encouraging findings, not beneath them.